A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2018
At a glance
- Drugs SAR 439794 (Primary) ; Glycopyranosyl lipid adjuvant
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors Sanofi
- 18 May 2018 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2019.
- 07 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.